To investigate whether targeting SNRPD3 methylation is an effective therapeutic strategy in MYCN-amplified neuroblastoma we assessed the effects of the PRMT5 inhibitor, JNJ-64619178 in vitro. Here, SNRPD3 is linked to neuroblastoma.